What's New in FGF23 Research?

Overview

Journal Bonekey Rep

Date 2013 Aug 17

PMID 23951494

Citations 1

Authors

Seiji Fukumoto

Affiliations

Soon will be listed here.

Abstract

FGF23 is a hormone that regulates phosphate and vitamin D metabolism by binding to Klotho-fibroblast growth factor (FGF) receptor complex. Excess actions of FGF23 cause several kinds of hypophosphatemic diseases. The mechanism of overproduction of FGF23 in some of these diseases is becoming clear, whereas it is not yet completely understood. Several specific methods to inhibit FGF23 actions have been reported as candidates for new therapies for these FGF23-related hypophosphatemic diseases. On the other hand, many epidemiological studies indicated the association between high FGF23 levels and several adverse events in cardiovascular system, kidney, bone and mortality. FGF23 was recently shown to induce ventricular hypertrophy in a Klotho-independent manner. However, it is not yet shown whether this Klotho-independent action of FGF23 can explain all the results of epidemiological studies.

Citing Articles

Unusual Association of Partial Fanconi Syndrome and Tumor-Induced Osteomalacia Revealed by Multiple Vertebral Fractures.

Debrach A, Coen M, de Seigneux S, Saiji E, Boudabbous S, Willi J Calcif Tissue Int. 2025; 116(1):36.

PMID: 39888445 PMC: 11785680. DOI: 10.1007/s00223-025-01344-2.

Musculoskeletal Health in the Context of Spinal Cord Injury.

Clark J, Findlay D Curr Osteoporos Rep. 2017; 15(5):433-442.

PMID: 28842819 DOI: 10.1007/s11914-017-0400-1.

References

Houston J, Smith K, Isakova T, Sowden N, Wolf M, Gutierrez O . Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease. J Ren Nutr. 2012; 23(1):12-20. PMC: 3378791. DOI: 10.1053/j.jrn.2011.12.009. View

Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I . Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009; 24(11):1879-88. DOI: 10.1359/jbmr.090509. View

Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke H, Choukroun G . FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. 2011; 23(7):2017-25. DOI: 10.1007/s00198-011-1838-0. View

Martin A, Liu S, David V, Li H, Karydis A, Feng J . Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J. 2011; 25(8):2551-62. PMC: 3136343. DOI: 10.1096/fj.10-177816. View

Plischke M, Neuhold S, Adlbrecht C, Bielesz B, Shayganfar S, Bieglmayer C . Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Invest. 2011; 42(6):649-56. DOI: 10.1111/j.1365-2362.2011.02631.x. View

Ranch D, Zhang M, Portale A, Perwad F . Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J Bone Miner Res. 2011; 26(8):1883-90. PMC: 4409871. DOI: 10.1002/jbmr.401. View

Nielsen S, Reinhard H, Zdunek D, Hess G, Gutierrez O, Wolf M . Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Res Clin Pract. 2012; 97(1):71-6. DOI: 10.1016/j.diabres.2012.02.007. View

Imel E, DiMeglio L, Hui S, Carpenter T, Econs M . Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab. 2010; 95(4):1846-50. PMC: 2853995. DOI: 10.1210/jc.2009-1671. View

Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H . Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008; 23(9):1509-18. DOI: 10.1359/jbmr.080417. View

10.

Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N . Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009; 45(4):814-6. DOI: 10.1016/j.bone.2009.06.017. View

11.

Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K . Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone. 2012; 50(6):1266-74. DOI: 10.1016/j.bone.2012.02.634. View

12.

Wohrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M . FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res. 2011; 26(10):2486-97. DOI: 10.1002/jbmr.478. View

13.

Farrow E, Yu X, Summers L, Davis S, Fleet J, Allen M . Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011; 108(46):E1146-55. PMC: 3219119. DOI: 10.1073/pnas.1110905108. View

14.

Fukumoto S, Shimizu Y . Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J Bone Miner Metab. 2011; 29(5):507-14. DOI: 10.1007/s00774-011-0298-0. View

15.

Isakova T, Xie H, Yang W, Xie D, Anderson A, Scialla J . Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305(23):2432-9. PMC: 3124770. DOI: 10.1001/jama.2011.826. View

16.

Feng J, Ward L, Liu S, Lu Y, Xie Y, Yuan B . Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006; 38(11):1310-5. PMC: 1839871. DOI: 10.1038/ng1905. View

17.

Schoppet M, Hofbauer L, Brinskelle-Schmal N, Varennes A, Goudable J, Richard M . Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. J Clin Endocrinol Metab. 2012; 97(4):E575-83. DOI: 10.1210/jc.2011-2836. View

18.

Stevens K, McQuarrie E, Sands W, Hillyard D, Patel R, Mark P . Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation. Int J Nephrol. 2011; 2011:297070. PMC: 3153939. DOI: 10.4061/2011/297070. View

19.

Semba R, Fink J, Sun K, Cappola A, Dalal M, Crasto C . Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Clin J Am Soc Nephrol. 2011; 7(1):85-91. PMC: 3265343. DOI: 10.2215/CJN.08070811. View

20.

Seiler S, Cremers B, Rebling N, Hornof F, Jeken J, Kersting S . The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J. 2011; 32(21):2688-96. DOI: 10.1093/eurheartj/ehr215. View